Satoko Ito, MD, PhD
Postdoctoral FellowAbout
Research
Publications
2026
Barriers to effective first-line treatment for women with iron deficiency
Rinaldi K, Ng D, Tadepalli A, Ito S, Goshua G, Wang D. Barriers to effective first-line treatment for women with iron deficiency. Expert Review Of Hematology 2026, ahead-of-print: 1-3. PMID: 42212667, DOI: 10.1080/17474086.2026.2683026.Peer-Reviewed Original ResearchHaploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Chetlapalli K, Ito S, Ng DQ, Sra MS, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G. Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood Journal 2026, blood.2025032290. DOI: 10.1182/blood.2025032290.Peer-Reviewed Original ResearchThis study investigates the cost-effectiveness of haploidentical stem cell transplantation, gene therapy, and standard care for sickle cell disease, showing transplantation offers the best value globally.JAKPOT Prediction Rule for Erythrocytosis: External Validation and Cost‐Effectiveness Analysis
Lam B, Ito S, Ryu J, O'Sullivan K, Potnis K, Lu R, Bidikian A, Ng D, Singh R, Deter A, Carfagnini C, Bechara S, Kandula M, Do N, Fillmore N, Freed J, Patell R, La J, Goshua G. JAKPOT Prediction Rule for Erythrocytosis: External Validation and Cost‐Effectiveness Analysis. American Journal Of Hematology 2026 PMID: 42227164, DOI: 10.1002/ajh.70390.Peer-Reviewed Original ResearchHaploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Chetlapalli K, Ito S, Ng D, Sra M, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G. Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood 2026 PMID: 42227898, DOI: 10.1182/blood.2025032290.Peer-Reviewed Original ResearchStandard-of-careAllo-HSCTGene therapyAllogeneic stem cell transplantationEra of gene therapyCost-effectiveness analysisStem cell transplantationPainful vaso-occlusive crisesIncremental cost-effectiveness ratioVaso-occlusive crisisCost-effectiveness ratioSickle cell diseaseHaploidentical transplantationCell transplantationBlood transfusionChronic anemiaProspective studyCost-effectiveness thresholdTreatment optionsPain managementDisease ameliorationPrimary outcomeSecondary outcomesCell diseaseBlood disordersCost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds
Wang D, Sra M, Ng D, Tadepalli A, Rinaldi K, Ito S, Cuker A, Goshua G. Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds. Blood Advances 2026 PMID: 42206692, DOI: 10.1182/bloodadvances.2026020143.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioCost-effectiveness analysisIron deficiencyPregnant womenRegular screeningDevelopmental deficitsCost-effectiveness ratioMaternal iron deficiencyThird-trimester screeningWorld Health OrganizationIron deficiency screeningTrimester of pregnancyClinical status quoID screeningPoor birth outcomesFerritin rangeMaternal morbidityTrimester screeningThird trimesterBirth outcomesDeficiency screeningProportion of mothersNo screeningInfusion timePregnant individualsCost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia
Ito S, Potnis K, Ng D, Patel K, Sra M, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia. Blood Red Cells & Iron 2026, 2: 100076. PMID: 42077391, PMCID: PMC13134686, DOI: 10.1016/j.brci.2026.100076.Peer-Reviewed Original ResearchThis study investigates how trainee-led teams developed updated consensus guidelines for managing peritoneal surface malignancies, demonstrating effective collaboration models for complex medical evidence synthesis."Cost-Effectiveness and Budget Impact of Facial Feminization Surgery".
Glaeser-Khan S, Shen Y, Wolbert T, Mukherjee T, Goshua G, Ito S, Alperovich M. "Cost-Effectiveness and Budget Impact of Facial Feminization Surgery". Plastic & Reconstructive Surgery 2026 PMID: 41940840, DOI: 10.1097/prs.0000000000013106.Peer-Reviewed Original ResearchU.S. dollarsInsurance coverageBudget impactLow budget impactFacial feminization surgeryMental health benefitsWTPIncremental cost-effectiveness ratioCost-effectiveness ratioBudget impact analysisMarkov cohort modelAspects of genderGender-affirming proceduresDollarsInsuranceU.S.Feminization surgeryTransgender womenImpact modelImpact analysisBudget impact modelCost-effectiveBudgetProbabilistic iterationsQALYCost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding
Wang D, Sra M, Ito S, Ng D, Glaeser-Khan S, Wang D, Hirniak S, Lee A, Cuker A, Goshua G. Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding. Blood Advances 2026, 10: 1508-1517. PMID: 41504430, PMCID: PMC12952766, DOI: 10.1182/bloodadvances.2025018315.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingIV iron dextranIron deficiency anemiaQuality-adjusted life yearsOral ferrous sulfateFirst-line treatmentIron dextranOral ironMenstrual bleedingCost-effective treatmentIron deficiencyFrequent gastrointestinal side effectsIV iron sucroseOral iron therapyFirst-line therapyQuality-adjusted life-year benefitsFirst-line optionIncremental cost-effectiveness ratioGastrointestinal side effectsCohort of womenCost-effectiveness ratioIron therapyIron sucroseIV ironTreatment delay
2025
Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis
Glaeser-Khan S, Ito S, Sra M, Richmond R, Bona R, Krumholz H, Croteau S, Cuker A, Goshua G. Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis. Blood Advances 2025, 9: 6237-6245. PMID: 40795232, PMCID: PMC12744270, DOI: 10.1182/bloodadvances.2025016822.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioSevere hemophilia AIntracranial hemorrhageEmicizumab prophylaxisHemophilia ASevere HAWTP thresholdStandard careProphylactic factor replacementUS societal perspectiveInfants Aged 0Markov cohort modelLifetime time horizonCost-effectiveness ratioProbabilistic sensitivity analysesFVIII inhibitorsBleeding riskFactor replacementSevere complicationsEmicizumabAccess placementCentral venous access placementPrimary outcomeProphylaxisNeurological disabilityUnderstanding Risk-Deleted Disability-Adjusted Life-Years What’s Left Behind
Goshua G, Wang D, Ito S, Ng D, Pandya A. Understanding Risk-Deleted Disability-Adjusted Life-Years What’s Left Behind. Journal Of The American College Of Cardiology 2025, 86: 2130-2132. PMID: 41298026, DOI: 10.1016/j.jacc.2025.09.1574.Peer-Reviewed Original Research
News
News
- December 05, 2024
Drug Offers Cost-Effective Protection for Newborns with Genetic Bleeding Disorder
- December 06, 2023
New Research Sheds Light on Equitable Treatment Options for Pediatric Patients With Sickle Cell Disease
- May 30, 2023
Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease
Get In Touch
Contacts
Email